Shares of biopharmaceutical company CytRx ( CYTR) gained 5.3% after the company said its RXi Pharmaceuticals subsidiary is licensing technology to the University of Massachusetts Medical School.

Shares were up 11 cents to $2.19 in premarket trading Thursday.

The exclusive license involves RNA interference, the company says. The university will also have the right to sublicense the so-called nanotransporter technology, which was shown to deliver RNA interference to different types of tissues in animal trials.

Financial terms were not disclosed.